Atlas Trials

Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL

Clinical trial NCT05239910 · WITHDRAWN

Trial details

NCT number
NCT05239910
Sponsor
Rhizen Pharmaceuticals SA
Status
WITHDRAWN
Phase
Phase 2
Study type
INTERVENTIONAL
Peripheral T Cell Lymphoma
Start date
2023-01-01
Primary completion
2026-12-01
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.